T
Timothy H. Self
Researcher at University of Tennessee Health Science Center
Publications - 187
Citations - 4360
Timothy H. Self is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Asthma & Warfarin. The author has an hindex of 28, co-authored 186 publications receiving 4105 citations. Previous affiliations of Timothy H. Self include Wingate University & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
The clinical and economic burden of chronic obstructive pulmonary disease in the USA.
TL;DR: With more than 50 new medications in the pipeline for the treatment of COPD, optimal management will continue to evolve and grow more complex as benefits of therapy are balanced with the limitations and needs of each patient.
Journal ArticleDOI
Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics
John J. Lima,Donald B. Thomason,Mohamad H.N. Mohamed,Louis V. Eberle,Timothy H. Self,Julie A. Johnson +5 more
TL;DR: To determine whether genetic polymorphisms of the β2‐adrenergic receptor gene affect the relationship between albuterol (INN, salbutamol) plasma concentrations and the forced expiratory volume in 1 second (FEV1) in subjects with moderate asthma, a genome-wide study is conducted.
Journal ArticleDOI
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
TL;DR: In this paper, the overall incidence of isoniazid (INH) hepatotoxicity in a public health tuberculosis clinic over a 7-year period, and to determine if systematic, limited aspartate aminotransferase (AST) monitoring would be of benefit in detecting INH hepatOToxicity.
Journal ArticleDOI
Rifampin and Rifabutin Drug Interactions: An Update
TL;DR: Clinicians need to be cognizant of rifampin and rifabutin interactions to avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampsin is added to or discontinued from medication regimens.
Journal ArticleDOI
Update on Rifampin Drug Interactions, III
TL;DR: New rifampin interactions have been described for cyclosporine, ketoconazole, chloramphenicol, beta-blockers, verapamil, and phenytoin that seem to be of clinical significance.